Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affimed stock logo
AFMD
Affimed
$5.03
+3.1%
$5.48
$2.23
$11.10
$76.61M2.0595,277 shs48,577 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.02
$0.02
$0.01
$3.75
$929K-1.12778,788 shs555,899 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.72
$1.92
$1.24
$11.85
$33.09M1.51390,863 shs104,621 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.19
-9.7%
$0.20
$0.09
$3.59
$10.12M2.172.35 million shs2.16 million shs
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$0.43
+2.4%
$0.51
$0.26
$3.28
$12.71M3.451.08 million shs218,746 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affimed stock logo
AFMD
Affimed
0.00%-3.75%-8.27%-14.08%-47.41%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-4.70%+0.71%-21.98%-59.31%-99.44%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.91%-4.97%-10.88%-16.50%-84.29%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+13.57%+11.56%+12.77%+16.90%-92.50%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
-0.87%-2.52%-13.23%-38.80%-82.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affimed stock logo
AFMD
Affimed
3.8226 of 5 stars
3.53.00.04.32.40.00.6
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.962 of 5 stars
3.52.00.00.00.63.30.6
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affimed stock logo
AFMD
Affimed
3.00
Buy$45.00794.63% Upside
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
2.00
HoldN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$30.001,644.19% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
1.75
ReduceN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/A

Current Analyst Ratings

Latest AFMD, EVFM, RDHL, GRTX, and FBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Affimed stock logo
AFMD
Affimed
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/1/2024
Affimed stock logo
AFMD
Affimed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$30.00 ➝ $25.00
4/1/2024
Affimed stock logo
AFMD
Affimed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00
3/19/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/15/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affimed stock logo
AFMD
Affimed
$8.95M8.56N/AN/A$4.19 per share1.20
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$18.22M0.05$1.68 per share0.01($2.64) per share-0.01
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$84.51M0.39N/AN/A$0.10 per share17.20
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$6.53M1.95$1.34 per share0.32$0.11 per share3.89

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affimed stock logo
AFMD
Affimed
-$114.66M-$8.40N/AN/AN/A-1,280.27%-118.17%-81.35%5/28/2024 (Estimated)
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$7.62N/AN/A290.81%-90.20%331.20%4/26/2024 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$60.64M-$8.22N/AN/AN/A-74.12%-770.86%-32.87%5/20/2024 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$1.41N/AN/AN/AN/A-137.47%5/9/2024 (Estimated)
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$23.92MN/A0.00N/AN/AN/AN/A6/10/2024 (Estimated)

Latest AFMD, EVFM, RDHL, GRTX, and FBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/A-$0.53-$0.53-$0.53$14.46 million$19.95 million
3/28/2024Q4 2023
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A-$0.10-$0.10-$0.10N/AN/A
3/27/2024Q4 2023
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A-$0.44-$0.44-$0.44N/A$4.84 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affimed stock logo
AFMD
Affimed
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affimed stock logo
AFMD
Affimed
0.11
3.25
3.23
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.13
0.10
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
38.42
1.38
1.26
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
4.36
4.36
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/A
0.84
0.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Affimed stock logo
AFMD
Affimed
30.82%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Affimed stock logo
AFMD
Affimed
3.80%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
33.40%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
6.90%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
6.81%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Affimed stock logo
AFMD
Affimed
21915.23 million14.65 millionOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
3755.46 million53.85 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
18719.24 million12.81 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
754.39 million50.64 millionOptionable
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
11329.70 million27.68 millionNo Data

AFMD, EVFM, RDHL, GRTX, and FBIO Headlines

SourceHeadline
RedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.comRedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - April 26 at 2:24 AM
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
finance.yahoo.com - April 24 at 11:40 AM
RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.comRedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
finance.yahoo.com - April 10 at 10:40 AM
Raleigh pharma weighs divesting commercial operationsRaleigh pharma weighs divesting commercial operations
bizjournals.com - April 9 at 1:31 PM
RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
finanznachrichten.de - April 8 at 4:40 PM
RedHill Biopharma Ltd. (2RH0.F)RedHill Biopharma Ltd. (2RH0.F)
finance.yahoo.com - April 8 at 4:40 PM
RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsRedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
prnewswire.com - April 8 at 9:23 AM
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
finance.yahoo.com - April 2 at 10:24 AM
RedHill announces new ten-year patent for TaliciaRedHill announces new ten-year patent for Talicia
thepharmaletter.com - March 11 at 12:39 PM
RedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaRedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia
markets.businessinsider.com - March 11 at 12:39 PM
RedHill Announces New USPTO Patent Covering Talicia® Through 2034RedHill Announces New USPTO Patent Covering Talicia® Through 2034
finance.yahoo.com - March 11 at 7:36 AM
RedHills Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
finance.yahoo.com - March 5 at 9:11 AM
RedHills Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
finance.yahoo.com - February 20 at 9:23 AM
RedHills Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
prnewswire.com - February 20 at 7:00 AM
RedHill Biopharma Ltd. ADRRedHill Biopharma Ltd. ADR
barrons.com - February 16 at 7:57 AM
RedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingRedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
finance.yahoo.com - January 26 at 8:38 PM
RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042
msn.com - January 25 at 9:37 AM
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
finance.yahoo.com - January 25 at 9:37 AM
RedHill Biopharma Announces $8 Million Registered Direct OfferingRedHill Biopharma Announces $8 Million Registered Direct Offering
finance.yahoo.com - January 25 at 9:37 AM
Why Redhill Biopharma Stock Is Moving HigherWhy Redhill Biopharma Stock Is Moving Higher
benzinga.com - January 24 at 12:27 PM
RedHills Investigational COVID-19 Drugs Combined With Gileads Show Effect Against EbolaRedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola
msn.com - December 20 at 6:33 PM
RedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus StudyRedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus Study
markets.businessinsider.com - December 20 at 1:32 PM
RedHill shares rally 20% on positive data for two antiviral drugsRedHill shares rally 20% on positive data for two antiviral drugs
msn.com - December 20 at 1:32 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Affimed logo

Affimed

NASDAQ:AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Evofem Biosciences logo

Evofem Biosciences

NASDAQ:EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Fortress Biotech logo

Fortress Biotech

NASDAQ:FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Galera Therapeutics logo

Galera Therapeutics

NASDAQ:GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
RedHill Biopharma logo

RedHill Biopharma

NASDAQ:RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.